167 related articles for article (PubMed ID: 30224501)
1. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R
Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501
[No Abstract] [Full Text] [Related]
2. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
[TBL] [Abstract][Full Text] [Related]
4. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
5. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
Ercan MB; Kocer B; Altiparmak T; Arslan I
Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
[No Abstract] [Full Text] [Related]
8. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
[TBL] [Abstract][Full Text] [Related]
9. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
[TBL] [Abstract][Full Text] [Related]
10. Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients.
Cordioli C; De Rossi N; Rasia S; Lodoli G; Capra R
Neurol Sci; 2015 Mar; 36(3):489-91. PubMed ID: 25109815
[No Abstract] [Full Text] [Related]
11. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ
Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016
[No Abstract] [Full Text] [Related]
12. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
[No Abstract] [Full Text] [Related]
13. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy.
Budhram A; Pelikan JB; Kremenchutzky M; Sharma M
J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156
[No Abstract] [Full Text] [Related]
14. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
[TBL] [Abstract][Full Text] [Related]
15. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.
Sinnecker T; Hadisurya J; Schneider-Hohendorf T; Schwab N; Wrede K; Gembruch O; Gold R; Hellwig K; Pilgram-Pastor S; Adams O; Albrecht P; Hartung HP; Aktas O; Kraemer M
BMC Neurol; 2019 Aug; 19(1):190. PubMed ID: 31399069
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M;
Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388
[TBL] [Abstract][Full Text] [Related]
17. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Tan LA; Lopes DK
J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
[TBL] [Abstract][Full Text] [Related]
18. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
Mahler C; Schumacher AM; Unterrainer M; Kaiser L; Höllbacher T; Lindner S; Havla J; Ertl-Wagner B; Patzig M; Seelos K; Neitzel J; Mäurer M; Krumbholz M; Metz I; Brück W; Stadelmann C; Merkler D; Gass A; Milenkovic V; Bartenstein P; Albert NL; Kümpfel T; Kerschensteiner M
Brain; 2021 Oct; 144(9):2683-2695. PubMed ID: 33757118
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
[TBL] [Abstract][Full Text] [Related]
20. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
